This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hervé, V. Articles by Maurel, M.-C. Search for Related Content PubMed PubMed Citation Articles by Hervé, V. Articles by Maurel, M.-C.

Antiequine Chorionic Gonadotropin (eCG) Antibodies Generated in Goats Treated with eCG for the Induction of Ovulation Modulate the Luteinizing Hormone and Follicle-Stimulating Hormone Bioactivities of eCG Differently

Laboratoire Mécanismes d’Action des Gonadotropines, Unité Mixte de Recherche 6073, Institut National de la Recherche Agronomique/Centre National de la Recherche Scientifique/Université de Tours, Station de Physiologie de la Reproduction des Mammifères Domestiques, 37380 Nouzilly, France

Address all correspondence and requests for reprints to: Dr. M. C. Maurel, Laboratoire Mécanismes d’Action des Gonadotropines, Unité Mixte de Recherche 6073, Institut National de la Recherche Agronomique/Centre National de la Recherche/Université de Tours, Station de Physiologie de la Reproduction des Mammifères Domestiques, 37380 Nouzilly, France. E-mail: maurel{at}tours.inra.fr.

In dairy goats, treatments associating a progestogen and the equine chorionic gonadotropin (eCG) are the easiest way to induce and synchronize estrus and ovulation and to permit artificial insemination (AI) and/or out of season breeding. From the first treatment, the injection of eCG induces, in some females, the production of anti-eCG antibodies (Abs) that will interfere with the effectiveness of subsequent treatments. These anti-eCG Abs delay the preovulatory LH surge and the ovulation time, leading to poor fertility of the treated females. In this study, by in vitro bioassays, we show that anti-eCG Abs can positively or negatively modulate the LH and/or FSH bioactivities of eCG. Moreover, the modulation level of eCG bioactivity does not depend on the anti-eCG Ab affinity for eCG, as shown by surface plasmon resonance technology. The specificity of anti-eCG Abs tested by competitive ELISA highlighted the importance of a glycan environment in the recognition mechanism, especially the sialic acids specific to eCG. The different effects of anti-eCG Abs on eCG bioactivities could be explained by two hypotheses. First, steric hindrance preventing the interaction of eCG with its receptors would explain the inhibitory effect of some anti-eCG Abs; second, a conformational change in eCG by anti-eCG Abs could induce inhibition or potentiation of eCG bioactivities. It is significant that these modulations of eCG bioactivities by anti-eCG Abs impact mainly on the FSH bioactivity of eCG, which is essential for ovarian stimulation and subsequent fertility after treatment and AI, and to a lesser extent on LH bioactivity.

This article has been cited by other articles:

				S. Legardinier, D. Klett, J.-C. Poirier, Y. Combarnous, and C. Cahoreau Mammalian-like nonsialyl complex-type N-glycosylation of equine gonadotropins in MimicTM insect cells Glycobiology, August 1, 2005; 15(8): 776 - 790. [Abstract] [Full Text] [PDF]